Breast Cancer Treatment during the COVID-19 Pandemic

Atul Batra; Prashant Mehta; Amol Patel; Sainath Bhethanabhotla; Bivas Biswas; Raja Pramanik; Chandan Krushna Das

doi:10.4103/ijmpo.ijmpo_111_20

Indian Journal of Medical and Paediatric Oncology, Table of Contents

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(02): 135-137
DOI: 10.4103/ijmpo.ijmpo_111_20

How I Treat

Breast Cancer Treatment during the COVID-19 Pandemic

Atul Batra

Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India

,

Prashant Mehta

Department of Medical Oncology, Hematoncology, and Bone Marrow Transplantation, Asian Institute of Medical Sciences, Faridabad, Haryana, India

,

Amol Patel

Malignant Diseases Treatment Centre, Army Hospital Research and Referral, New Delhi, India

,

Sainath Bhethanabhotla

Department of Medical Oncology, Krishna Institute of Medical Sciences, Hyderabad, Telangana, India

,

Bivas Biswas

Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India

,

Raja Pramanik

Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India

,

Chandan Krushna Das

Department of Medical Oncology, PGI, Chandigarh, India

› Author Affiliations

Abstract

Full Text

References

References
1 Globocan 2018: India Factsheet. India against Cancer. 2018 http://cancerindia.org.in/globocan-2018-india-factsheet/ October Available from: [Last accessed on 2020 Apr 07]
2 Predict Breast. https://breast.predict.nhs.uk/tool Available from: [Last accessed on 2020 Mar 23]
3 Team TNCPERE. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) — China, 2020. CCDCW 2020; 2: 113-22
4 Liang W, Guan W, Chen R, Wang W, Li J, Xu K. et al. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol 2020; 21: 335-7
5 Wang H, Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol 2020; 21: e181
6 Earl HM, Hiller L, Vallier A-L, Loi S, McAdam K, Hughes-Davies L. et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. The Lancet 2019; 393: 2599-612
7 Diaz JH. Hypothesis: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med 2020; pii: taaa041
8 Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi-Zoccai G. et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol 2020; pii S0735-1097 (20) 34637-4
9 http://Breast-Resource-During-COVID-19-3.30.20.pdf Available from: [Last accessed on 2020 Apr 07]
10 Wang SL, Fang H, Song YW, Wang WH, Hu C, Liu YP. et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: A randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 2019; 20: 352-60
11 Correa C, Harris EE, Leonardi MC, Smith BD, Taghian AG, Thompson AM. et al. Accelerated partial breast irradiation: Executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol 2017; 7: 73-9
12 http://Telemedicine.pdf Available from: [Last accessed on 2020 Apr 07]